15.265 articles found

Dynamic cortical inhibition imbalance as a biomarker of clinical progression in early Parkinson's disease.

Li P, Zhou X, Luo N, Zhou S, Yin Q, Zhou L, Liu J.

Neurobiol Dis · 2025-09-03

DOI: 10.1016/j.nbd.2025.107083PMID: 40912410

Frailty in Patients With Parkinson's Disease in Community and Clinical Settings: A Scoping Review.

Lee J, Park J, Yoo S, Kim E, Yoo JH.

West J Nurs Res · 2025-09-03

DOI: 10.1177/01939459251365725PMID: 40899376

Faster disease progression in Parkinson's disease with glucocerebrosidase genotype: But not apparent immediate from diagnosis.

Frequin HL, Ferwerda B, Verschuur CV, Suwijn SR, Dijk JM, de Bie RM, LEAP Study Group.

J Parkinsons Dis · 2025-09-03

DOI: 10.1177/1877718x251361507PMID: 40899843

Cranial glucose metabolic patterns across prodromal and clinical parkinson's disease revealed by <sup>18</sup>F-FDG PET.

Lu W, Song T, Zhou Y, Zeng Q, Li J, Cui B, Lu J.

Eur J Nucl Med Mol Imaging · 2025-09-03

DOI: 10.1007/s00259-025-07533-3PMID: 40900316

A Scientometric Analysis of Bias and Fairness in Parkinson's Disease Clinical Assessment Scales

Benjelloun M, Botta R, Celi LA, Hani M, Mahmoudi S, Nageswaran N, Ong B, Restrepo D, Vilardo M.

· 2025-09-02

DOI: 10.20944/preprints202509.0253.v1

Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson's Disease.

Kaye AD, Ford BM, Abbott BM, Broocks KM, Novacic S, Shekoohi S.

Diseases · 2025-09-02

DOI: 10.3390/diseases13090290PMID: 41002726

An In Vitro-In Vivo Comparison of Two Levodopa Dry Powder Products for Inhalation: A Randomized Trial Comparing Inbrija and Levodopa Cyclops.

Berends JME, Wimmenhove EJ, Hoppentocht M, Hagedoorn P, Frijlink HW, Grasmeijer F.

Pharmaceutics · 2025-09-02

DOI: 10.3390/pharmaceutics17091149PMID: 41012486

A double-blind, controlled trial of circadian effective light therapy in patients with Parkinson's disease.

Wyman BT, Adams D, Hendrix S, Groves J, Croft W, Ellison N, Olanow CW, Kieburtz K.

Neurotherapeutics · 2025-09-02

DOI: 10.1016/j.neurot.2025.e00728PMID: 40903343

Critical insights on "advanced clinical stage parkinson's disease is linked to pro inflammatory and regulatory blood cell populations."

Amjad M, Ahmad B, Amjad S.

Neurol Sci · 2025-09-02

DOI: 10.1007/s10072-025-08460-9PMID: 40892173

Add-on therapies to levodopa improve pain modulation in Parkinson's disease with motor fluctuations: A prospective cohort study.

Andrenelli E, Baldini N, Barbini FA, Benedetti M, Brambatti J, Capecci M, Ceravolo MG.

Parkinsonism Relat Disord · 2025-09-02

DOI: 10.1016/j.parkreldis.2025.108019PMID: 40939528

Sidransky Syndrome and Idiopathic Parkinson’s Disease: A Comparative Two-Year Clinical Analysis in Albanian Patients

BASHA¹ E, TOMORI² S, ZLLAMI³ B, CULLUFI² P.

· 2025-09-01

DOI: 10.21203/rs.3.rs-7232085/v1

Clinical insights into catechin-based nanomedicine: a review of therapeutic potential in neurodegenerative diseases

Al Amin M, Zehravi M, Sweilam SH, Shanmugarajan TS, Arjun UVNV, Nagaiyan MB, Reddy SM, Subash V, swarnalatha KM, Pazhanikumar A, Mart J, Prasad PD, Khan MI, Ahmad I, Emran TB.

3 Biotech · 2025-09-01